EVOLUS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
EVOLUS, INC. (EOLS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$6.58 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2020-08-10
- 2020-06-30: Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month -$6.58M.
- 2019-06-30: Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month $13.35M.
- 2018-06-30: Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month $2.40M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month |
|---|---|
| 2020-06-30 | -$6.58M 10-Q · filed 2020-08-10 |
| 2019-06-30 | $13.35M 10-Q · filed 2020-08-10 |
| 2018-06-30 | $2.40M 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |